Proteinea

Proteinea is a private, AI-driven biotech founded in 2021 and headquartered in Cambridge, Massachusetts. The company has developed a proprietary computational platform for the rational engineering of antibody Fc domains to precisely tune immune function, enhance half-life, and control biodistribution. By combining AI-driven prediction with streamlined experimental workflows, Proteinea seeks to accelerate the development of differentiated biologic therapeutics and reduce downstream failure rates. It operates as a platform technology company and is currently in a pre-revenue, pre-clinical stage, supported by a network of partners and supporters.

Proprietary AI-driven platform for rational engineering of antibody Fc domains, combining deep-learning prediction models with smart experimental validation to design scaffolds with tuned immune function, enhanced half-life, and improved developability.

Proteinea competes in the crowded AI-driven drug discovery space, facing competition from pure-play AI biotechs (e.g., Absci, Generate Biomedicines) and internal efforts at large biopharma companies. Its focused niche on Fc engineering differentiates it, but it must prove superior predictive power and translational success.